2023
Hashimoto M, Yonezawa S, Furan S, Nitta C, Maeda N, Tomita K, Yokouchi A, Koide H, Asai T. Increasing the siRNA knockdown efficiency of lipid nanoparticles by morphological transformation with the use of dihydrosphingomyelin as a helper lipid. Biomater Sci. 11, 3269-3277 (2023) doi: 10.1039/d3bm00068k.
Asai T, Yokota M, Isomura H, Koide H, Sakurai N, Okamoto A, Ando H, Dewa T, Oku N. Treatment of PTEN-Null Breast Cancer by a Synthetic Lethal Approach Involving PARP1 Gene Silencing. J Pharm Sci. 112, 1908-1914 (2023) doi: 10.1016/j.xphs.2023.02.017.
Koide H, Saito K, Yoshimatsu K, Chou B, Hoshino Y, Yonezawa S, Oku N, Asai T, Shea KJ. Cooling-induced, localized release of cytotoxic peptides from engineered polymer nanoparticles in living mice for cancer therapy. J Control Release. 335, 745-759 (2023) doi: 10.1016/j.jconrel.2023.02.020.
2022
Koide H, Ochiai H, Suzuki H, Hirata S, Watanabe M, Yonezawa S, Dewa T, Oku N, Asai T. Easy preparation of a liposome-mediated protein delivery system by freeze-thawing a liposome-protein complex. J Mater Chem B. (2022) doi: 10.1039/d2tb00271j.
Minami K, Kataoka M, Takagi T, Asai T, Oku N, Yamashita S. Liposomal Formulation for Oral Delivery of Cyclosporine A: Usefulness as a Semisolid-Dispersion System. Pharm Res. 39, 977-987 (2022) doi: 10.1007/s11095-022-03276-0.
2021
Hirai Y, Hirose H, Imanishi M, Asai T, Futaki S. Cytosolic protein delivery using pH-responsive, charge-reversible lipid nanoparticles. Scientific Reports. 11, 19896 (2021) doi: 10.1038/s41598-021-99180-5.
Koide H, Okishima A, Hoshino Y, Kamon Y, Yoshimatsu K, Saito K, Yamauchi I, Ariizumi S, Zhou Y, Xiao TH, Goda K, Oku N, Asai T, Shea KJ. Synthetic hydrogel nanoparticles for sepsis therapy. Nature Communications. 12, 5552 (2021) doi: 10.1038/s41467-021-25847-2.
Koide H. Design of Synthetic Polymer Nanoparticles That Capture and Neutralize Target Molecules. YAKUGAKU ZASSHI. 141, 1079-1086 (2021) doi: 10.1248/yakushi.21-00125.
Koide H. Design of Functional Nanoparticles for Intractable Disease Therapy. Biol Pharm Bull. 44, 1-6 (2021) doi: 10.1248/bpb.b20-00699.
Koide H, Yonezawa S, Asai T. siRNA Vehicles for High Endosomal Escapability. Methods Mol Biol. 2282,171-179 (2021) doi: 10.1007/978-1-0716-1298-9_11.
Koide H, Suzuki H, Ochiai H, Egami H, Hamashima Y, Oku N, Asai T. Enhancement of target toxin neutralization effect in vivo by PEGylation of multifunctionalized lipid nanoparticles. Biochem Biophys Res Commun. 555, 32-39 (2021) doi: 10.1016/j.bbrc.2021.03.073.
Koide H, Hayashi N, Yasuno G, Okishima A, Hoshino Y, Egami H, Hamashima Y, Oku N, Asai T. Design of synthetic polymer nanoparticles that inhibit glucose absorption from the intestine. Biochem Biophys Res Commun. 561, 1-6 (2021) doi: 10.1016/j.bbrc.2021.05.005.
Koide H, Yamauchi I, Hoshino Y, Yasuno G, Okamoto T, Akashi S, Saito K, Oku N, Asai T. Design of abiotic polymer ligand-decorated lipid nanoparticles for effective neutralization of target toxins in the blood. Biomater Sci. 9, 5588-5598 (2021) doi: 10.1039/d1bm00515d.
Yasuno G, Koide H, Oku N, Asai T. Influence of Purification Process on the Function of Synthetic Polymer Nanoparticles. Chem Pharm Bull. 69, 773-780 (2021) doi: 10.1248/cpb.c21-00273.
Shimizu K, Agata K, Takasugi S, Goto S, Narita Y, Asai T, Magata Y, Oku N. New strategy for MS treatment with autoantigen-modified liposomes and their therapeutic effect. J Control Release. 335, 389-397 (2021) doi: 10.1016/j.jconrel.2021.05.027.
Onuma S, Manabe A, Yoshino Y, Matsunaga T, Asai T, Ikari A. Upregulation of Chemoresistance by Mg2+ Deficiency through Elevation of ATP Binding Cassette Subfamily B Member 1 Expression in Human Lung Adenocarcinoma A549 Cells. Cells. 10, 1179 (2021) doi: 10.3390/cells10051179.
Numata M, Hirano A, Yamamoto Y, Yasuda M, Miura N, Sayama K, Shibata MA, Asai T, Oku N, Miyoshi N, Shimoi K. Metastasis of Breast Cancer Promoted by Circadian Rhythm Disruption due to Light/Dark Shift and its Prevention by Dietary Quercetin in Mice. J Circadian Rhythms. 19, 2 (2021) doi: 10.5334/jcr.203.
2020
Yonezawa S, Koide H, Asai T. Recent advances in siRNA delivery mediated by lipid-based nanoparticles. Adv Drug Deliv Rev. 154-155, 64-78 (2020) doi: 10.1016/j.addr.2020.07.022.
Koide H, Hirano S, Ide T, Saito K, Suzuki H, Yasuno G, Hamashima Y, Yonezawa S, Oku N, Asai T. Engineering of lipid nanoparticles by the multifunctionalization of the surface with amino acid derivatives for the neutralization of a target toxic peptide. Adv.Funct.Mater. 2005641 (2020)
Yanagida Y, Namba M, Fukuta T, Yamamoto H, Yanagida M, Honda M, Oku N, Asai T. Release rate is a key variable affecting the therapeutic effectiveness of liposomal fasudil for the treatment of cerebral ischemia/reperfusion injury. Biochem Biophys Res Commun. 531, 622-627 (2020) doi: 10.1016/j.bbrc.2020.07.038.
Hirai Y, Saeki R, Song F, Koide H, Fukata N, Tomita K, Maeda N, Oku N, Asai T. Charge-reversible lipid derivative: A novel type of pH-responsive lipid for nanoparticle-mediated siRNA delivery. Int J Pharm. 585, 119479 (2020) doi: 10.1016/j.ijpharm.2020.119479.
Nasako H, Akizuki R, Takashina Y, Ishikawa Y, Shinoda T, Shirouzu M, Asai T, Matsunaga T, Endo S, Ikari A. Claudin-2 binding peptides, VPDSM and DSMKF, down-regulate claudin-2 expression and anticancer resistance in human lung adenocarcinoma A549 cells. Biochim Biophys Acta Mol Cell Res. 1867, 118642 (2020) doi: 10.1016/j.bbamcr.2019.118642.
Minami K, Takazawa A, Taniguchi Y, Higashino H, Kataoka M, Asai T, Oku N, Yamashita S. Challenge for oral delivery of middle-molecular drugs: Use of osmolarity-sensitive liposome as a drug carrier in the GI tract. J Drug Deliv Sci Technol. 56, 101041 (2020) doi: 10.1016/j.jddst.2019.04.035
Shimizu K, Takeuchi Y, Otsuka K, Mori T, Narita Y, Takasugi S, Magata Y, Matsumura Y, Oku N. Development of tissue factor-targeted liposomes for effective drug delivery to stroma-rich tumors. J Control Release. 323, 519-529 (2020) doi: 10.1016/j.jconrel.2020.04.043.
2019
Kikuchi T, Fukuta T, Agato Y, Yanagida Y, Ishii T, Koide H, Shimizu K, Oku N, Asai T: Suppression of cerebral ischemia/reperfusion injury by efficient release of encapsulated ifenprodil from liposomes under weakly acidic pH conditions J. Pharm. Sci., 108, 3823-3830 (2019) doi: 10.1016/j.xphs.2019.09.006.
Koide H, Fukuta T, Okishima A, Ariizumi S, Kiyokawa C, Tsuchida H, Nakamoto M, Yoshimatsu K, Ando H, Dewa T, Asai T, Oku N, Hoshino Y, Shea KJ: Eng
ineering the binding kinetics of synthetic polymer nanoparticles for siRNA delivery Biomacromolecules, 20, 3648-3657 (2019) doi: 10.1021/acs.biomac.9b00611.
Sako M, Song F, Okamoto A, Koide H, Dewa T, Oku N, Asai T. Key determinants of siRNA delivery mediated by unique pH-responsive lipid-based liposomes. Int. J. Pharm. 569, 118606 (2019) doi: 10.1016/j.ijpharm.2019.118606.
Song F, Sakurai N, Okamoto A, Koide H, Oku N, Dewa T, Asai T. Design of a Novel PEGylated Liposomal Vector for Systemic Delivery of siRNA to Solid Tumors. Biol. Pharm. Bull. 42, 996-1003 (2019) doi: 10.1248/bpb.b19-00032.
Okishima A, Koide H, Hoshino Y, Egami H, Hamashima Y, Oku N, Asai T. Design of Synthetic Polymer Nanoparticles Specifically Capturing Indole, a Small Toxic Molecule. Biomacromolecules. 20, 1644-1654 (2019) doi: 10.1021/acs.biomac.8b01820.
Fukuta T, Ishii T, Asai T, Oku N. Applications of Liposomal Drug Delivery Systems to Develop Neuroprotective Agents for the Treatment of Ischemic Stroke. Biol. Pharm. Bull. 42, 319-326 (2019) doi: 10.1248/bpb.b18-00683.
Okamoto A, Koide H, Morita N, Hirai Y, Kawato Y, Egami H, Hamashima Y, Asai T, Dewa T, Oku N. Rigorous control of vesicle-forming lipid pKa by fluorine-conjugated bioisosteres for gene-silencing with siRNA. J. Control. Release. 295, 87-92 (2019) doi: 10.1016/j.jconrel.2018.12.044.
Koide H, Yoshimatsu K, Hoshino Y, Ariizumi S, Okishima A, Ide T, Egami H, Hamashima Y, Nishimura Y, Kanazawa H, Miura Y, Asai T, Oku N, Shea KJ: Sequestering and inhibiting a vascular endothelial growth factor in vivo by systemic administration of a synthetic polymer nanoparticle. J. Control. Release., 295, 13-20 (2019) doi: 10.1016/j.jconrel.2018.12.033.
Zang L, Shimada Y, Nakayama H, Chen W, Okamoto A, Koide H, Oku N, Dewa T, Shiota M, Nishimura N: Therapeutic Silencing of Centromere Protein X Ameliorates Hyperglycemia in Zebrafish and Mouse Models of Type 2 Diabetes Mellitus. Front Genet., 10, 693 (2019) doi: 10.3389/fgene.2019.00693. eCollection 2019.
Yonezawa S, Abe M, Kawasaki Y, Natori Y, Sugiyama A: Each liver X receptor (LXR) type has a different purpose in different situations. Biochem. Biophys. Res. Commun., 508, 92-96 (2019) doi: 10.1016/j.bbrc.2018.11.076. Epub 2018 Nov 22.
2018
Koide H, Yoshimatsu K, Hoshino Y, Ariizumi S, Okishima A, Ide T, Egami H, Hamashima Y, Nishimura Y, Kanazawa H, Miura Y, Asai T, Oku N, Shea KJ. Sequestering and inhibiting a vascular endothelial growth factor in vivo by systemic administration of a synthetic polymer nanoparticle. J. Control. Release. 295, 13-20 (2019) doi: 10.1016/j.jconrel.2018.12.033.
Yamaguchi Ikeuchi S, Kambayashi A, Kojima H, Oku N, Asai T: Prediction of the oral pharmacokinetics and food effects of gabapentin enacarbil extended-release tablets using biorelevant dissolution tests. Biol. Pharm. Bull. 41, 1708-1715 (2018) doi: 10.1248/bpb.b18-00456.
Yahuafai J, Asai T, Oku N, Siripong P: Anticancer Efficacy of the Combinat ion of berberine and PEGylated liposomal doxorubicin in Meth A sarcoma-bearing mice. Biol. Pharm. Bull. 41, 1103-1106 (2018) doi: 10.1248/bpb.b17-00989.
Okamoto A, Asai T, Hirai Y, Shimizu K, Koide H, Minamino T, Oku N: Systemic administration of siRNA with anti-HB-EGF antibody-modified lipid nanoparticles for the treatment of triple-negative breast cancer. Mol Pharm. 15, 1495-1504 (2018) doi:10.1021/acs.molpharmaceut.7b01055
Fukuta T, Yanagida Y, Asai T, Oku N: Co-administration of liposomal fasudil and tissue plasminogen activator ameliorated ischemic brain damage in occlusion model rats prepared by photochemically induced thrombosis. Biochem. Biophys. Res. Commun. 495, 873-877 (2018) doi: 10.1016/j.bbrc.2017.11.107
Shimizu K, Ikeuchi SY, Okajima A, Nakamura G, Muraoka E, Oku N: Involvement of tumor lymphatic system in translocation of intratumorally injected liposomes.Biol. Pharm. Bull. 41, 652-656 (2018) doi: 10.1248/bpb.b17-00730.
2017
Koide H, Tsuchida H, Nakamoto M, Okishima A, Ariizumi S, Kiyokawa C, Asai T, Hoshino Y, Oku N: Rational designing of an antidote nanoparticle decorated with abiotic polymer ligands for capturing and neutralizing target toxins. J. Control. Release. 68, 335-342 (2017) doi: 10.1016/j.jconrel.2017.10.028.
Fukuta T, Asai T, Kiyokawa Y, Nakada T, Bessyo-Hirashima K, Fukaya N, Hyodo K, Takase K, Kikuchi H, Oku N: Targeted delivery of anticancer drugs to tumor vessels by use of liposomes modified with a peptide identified by phage biopanning with human endothelial progenitor cells. Int. J. Pharm. 524, 364-372 (2017) doi: 10.1016/j.ijpharm.2017.03.059.
Toyota H, Asai T, Oku N: Process optimization by use of design of experiments: Application for liposomalization of FK506. Eur. J. Pharm. Sci. 102, 196-202 (2017) doi: 10.1016/j.ejps.2017.03.007.
Koide H, Yoshimatsu K, Hoshino Y, Lee SH, Okajima A, Ariizumi S, Narita Y, Yonamine Y, Weisman AC, Nishimura Y, Oku N, Miura Y, Shea KJ: A polymer nanoparticle with engineered affinity for a vascular endothelial growth factor (VEGF165). Nat Chem. 9, 715-722 (2017) doi: 10.1038/nchem.2749.
Oku N: Innovations in liposomal DDS technology and its application for the treatment of various diseases. Biol Pharm Bull. 40, 119-127 (2017) doi: 10.1248/bpb.b16-00857.
Fukuta T, Asai T, Yanagida Y, Namba M, Koide H, Shimizu K, Oku N: Combination therapy with liposomal neuroprotectants and tissue plasminogen activator for treatment of ischemic stroke. FASEB J. 31, 1879-1890 (2017) doi: 10.1096/fj.201601209R.